Access the full text.
Sign up today, get DeepDyve free for 14 days.
J. Jonas (2006)
Intravitreal Triamcinolone Acetonide: A Change in a ParadigmOphthalmic Research, 38
P. Beer, S. Bakri, Ravinder Singh, Weiguo Liu, G. Peters, Michael Miller (2003)
Intraocular concentration and pharmacokinetics of triamcinolone acetonide after a single intravitreal injection.Ophthalmology, 110 4
K. Wilson, M. McCartney, S. Miggans, A. Clark (1993)
Dexamethasone induced ultrastructural changes in cultured human trabecular meshwork cells.Current eye research, 12 9
JM DeFaller, AF Clarke
A new pharmacologic treatment for angiogenesis.
A. Konstantopoulos, C. Williams, RS Newsom, A. Luff (2007)
Ocular morbidity associated with intravitreal triamcinolone acetonideEye, 21
R. Wordinger, Abbot Clarka (1999)
Effects of glucocorticoids on the trabecular meshwork: towards a better understanding of glaucomaProgress in Retinal and Eye Research, 18
Xinyu Zhang, C. Ognibene, A. Clark, T. Yorio (2007)
Dexamethasone inhibition of trabecular meshwork cell phagocytosis and its modulation by glucocorticoid receptor beta.Experimental eye research, 84 2
J. Penn, V. Rajaratnam, R. Collier, A. Clark (2001)
The effect of an angiostatic steroid on neovascularization in a rat model of retinopathy of prematurity.Investigative ophthalmology & visual science, 42 1
MF Armaly (1963)
Effect of corticosteroids on intraocular pressure and fluid dynamics II: the effect of dexamethasone in the glaucomatous eye., 70
D. D’Amico, M. Goldberg, H. Hudson, J. Jerdan, S. Krueger, Susan Luna, S. Robertson, S. Russell, L. Singerman, J. Slakter, E. Sullivan, L. Yannuzzi, P. Zilliox (2003)
ANECORTAVE ACETATE AS MONOTHERAPY FOR THE TREATMENT OF SUBFOVEAL LESIONS IN PATIENTS WITH EXUDATIVE AGE-RELATED MACULAR DEGENERATION (AMD): Interim (Month 6) Analysis of Clinical Safety and EfficacyRETINA, 23
A. Clark (1997)
AL-3789: a novel ophthalmic angiostatic steroid.Expert opinion on investigational drugs, 6 12
L. Mcnatt, L. Weimer, J. Yanni, Abbot Clark (1999)
Angiostatic activity of steroids in the chick embryo CAM and rabbit cornea models of neovascularization.Journal of ocular pharmacology and therapeutics : the official journal of the Association for Ocular Pharmacology and Therapeutics, 15 5
J. Jonas, R. Degenring, I. Kreissig, I. Akkoyun, B. Kamppeter (2005)
Intraocular pressure elevation after intravitreal triamcinolone acetonide injection.Ophthalmology, 112 4
M. Armaly (1963)
EFFECT OF CORTICOSTEROIDS ON INTRAOCULAR PRESSURE AND FLUID DYNAMICS. I. THE EFFECT OF DEXAMETHASONE IN THE NORMAL EYE.Archives of ophthalmology, 70
J. Jonas, R. Degenring, B. Kamppeter, I. Kreissig, I. Akkoyun (2004)
Duration of the effect of intravitreal triamcinolone acetonide as treatment for diffuse diabetic macular edema.American journal of ophthalmology, 138 1
D. Rhee, R. Peck, J. Belmont, A. Martidis, Mimi Liu, Jeffrey Chang, J. Fontanarosa, M. Moster (2006)
Intraocular pressure alterations following intravitreal triamcinolone acetonideBritish Journal of Ophthalmology, 90
L. Smithen, Michael Ober, L. Maranan, R. Spaide (2004)
Intravitreal triamcinolone acetonide and intraocular pressure.American journal of ophthalmology, 138 5
D. D’Amico, M. Goldberg, H. Hudson, J. Jerdan, D. Krueger, Susan Luna, S. Robertson, S. Russell, L. Singerman, J. Slakter, L. Yannuzzi, P. Zilliox (2003)
Anecortave acetate as monotherapy for treatment of subfoveal neovascularization in age-related macular degeneration: twelve-month clinical outcomes.Ophthalmology, 110 12
A. Clark, K. Wilson, M. McCartney, S. Miggans, M. Kunkle, W. Howe (1994)
Glucocorticoid-induced formation of cross-linked actin networks in cultured human trabecular meshwork cells.Investigative ophthalmology & visual science, 35 1
CLINICAL SCIENCES Reduction of Intraocular Pressure With Anecortave Acetate in Eyes With Ocular Steroid Injection–Related Glaucoma Alan L. Robin, MD; Eric P. Suan, MD; Raymond N. Sjaarda, MD; David G. Callanan, MD; Joseph DeFaller, PhD†; for the Alcon Anecortave Acetate for IOP Research Team Objective: To evaluate the intraocular pressure (IOP)– Results: The mean baseline IOP was 39.9 mm Hg. After lowering potential of anecortave acetate (AA) in eyes with 1 week, the mean IOP decreased 12 mm Hg (29%; P = .005) steroid-related ocular hypertension inadequately con- and by 1 month, the mean IOP had decreased 14.1 mm Hg trolled with the maximal tolerated or appropriate medi- (34.5%; P = .003) from baseline. Four eyes required surgi- cal therapy. cal intervention despite a decrease in IOP because of mark- edly elevated initial IOP and the degree of preexisting glau- Design: Uncontrolled case series. comatous optic neuropathy. We observed no adverse events. Methods: A total of 8 eyes of 7 subjects with medically Conclusions: An anterior juxtascleral depot of AA low- uncontrolled IOP following intravitreal or sub-Tenon in- ers IOP substantially in some eyes with medically un- jections of triamcinolone acetonide were included. All controlled steroid-related ocular hypertension. Further
JAMA Ophthalmology – American Medical Association
Published: Feb 1, 2009
Read and print from thousands of top scholarly journals.
Already have an account? Log in
Bookmark this article. You can see your Bookmarks on your DeepDyve Library.
To save an article, log in first, or sign up for a DeepDyve account if you don’t already have one.
Copy and paste the desired citation format or use the link below to download a file formatted for EndNote
Access the full text.
Sign up today, get DeepDyve free for 14 days.
All DeepDyve websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.